Cargando…

Targeted next generation sequencing in Chinese colorectal cancer patients guided anti-EGFR treatment and facilitated precision cancer medicine

OBJECTIVE: Colorectal cancer (CRC) patients with both RAS and BRAF wild-type tumors determined by non-next generation sequencing (NGS) testing may still not respond due to the presence of additional mutated genes such as PIK3CA or PTEN. In this study, a broad, hybrid capture-based NGS assay was used...

Descripción completa

Detalles Bibliográficos
Autores principales: Hou, Helei, Liu, Dong, Zhang, Chuantao, Jiang, Yanxia, Lu, Guifang, Zhou, Na, Yang, Xiaonan, Zhang, Xiaoping, Li, Zhuokun, Zhu, Hongmei, Qian, Zhaoyang, Zhang, Xiaochun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5739621/
https://www.ncbi.nlm.nih.gov/pubmed/29285234
http://dx.doi.org/10.18632/oncotarget.21349
_version_ 1783287900170878976
author Hou, Helei
Liu, Dong
Zhang, Chuantao
Jiang, Yanxia
Lu, Guifang
Zhou, Na
Yang, Xiaonan
Zhang, Xiaoping
Li, Zhuokun
Zhu, Hongmei
Qian, Zhaoyang
Zhang, Xiaochun
author_facet Hou, Helei
Liu, Dong
Zhang, Chuantao
Jiang, Yanxia
Lu, Guifang
Zhou, Na
Yang, Xiaonan
Zhang, Xiaoping
Li, Zhuokun
Zhu, Hongmei
Qian, Zhaoyang
Zhang, Xiaochun
author_sort Hou, Helei
collection PubMed
description OBJECTIVE: Colorectal cancer (CRC) patients with both RAS and BRAF wild-type tumors determined by non-next generation sequencing (NGS) testing may still not respond due to the presence of additional mutated genes such as PIK3CA or PTEN. In this study, a broad, hybrid capture-based NGS assay was used to identify RAS, BRAF and additional targetable genetic alterations from Chinese CRC tissues. METHODS: Fifty-seven cases of CRC were enrolled, and all the patients signed the informed consent. In total, 7708 exons of 508 tumor-related genes and 78 introns of 19 frequently rearranged genes were assessed for base substitutions, INDELs, copy number alterations, and gene fusions. RESULTS: The study found that 50.9% (29/57) of the tumors harbored KRAS mutations, 3.5% (2/57) harbored NRAS mutations and 3.5% (2/57) harbored BRAF mutations. More specifically, 89.7% (26/29) of RAS mutations were located in codon 12. Except for RAS and RAF, anti-EGFR therapy response genetic mutations in PTEN (n=2) and PIK3CA (n=1) were found in 4.7% (3/64) of the samples. Actionable alterations were found in HER2 (n = 7), CCND2 (n = 2), NF1 (n = 1), and BRCA1 (n = 1). CONCLUSIONS: Our results illustrated that 82.5% (47/57) of the samples harbored at least one actionable genetic alteration identified by NGS. HER2 amplifications or mutations, which were identified in 12.3% of the tissues, defined a unique molecular subtype of CRC. The study suggests that high-throughput NGS testing in CRC tissues is a comprehensive and efficient genomic profiling assay to guide personalized therapy.
format Online
Article
Text
id pubmed-5739621
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-57396212017-12-28 Targeted next generation sequencing in Chinese colorectal cancer patients guided anti-EGFR treatment and facilitated precision cancer medicine Hou, Helei Liu, Dong Zhang, Chuantao Jiang, Yanxia Lu, Guifang Zhou, Na Yang, Xiaonan Zhang, Xiaoping Li, Zhuokun Zhu, Hongmei Qian, Zhaoyang Zhang, Xiaochun Oncotarget Research Paper OBJECTIVE: Colorectal cancer (CRC) patients with both RAS and BRAF wild-type tumors determined by non-next generation sequencing (NGS) testing may still not respond due to the presence of additional mutated genes such as PIK3CA or PTEN. In this study, a broad, hybrid capture-based NGS assay was used to identify RAS, BRAF and additional targetable genetic alterations from Chinese CRC tissues. METHODS: Fifty-seven cases of CRC were enrolled, and all the patients signed the informed consent. In total, 7708 exons of 508 tumor-related genes and 78 introns of 19 frequently rearranged genes were assessed for base substitutions, INDELs, copy number alterations, and gene fusions. RESULTS: The study found that 50.9% (29/57) of the tumors harbored KRAS mutations, 3.5% (2/57) harbored NRAS mutations and 3.5% (2/57) harbored BRAF mutations. More specifically, 89.7% (26/29) of RAS mutations were located in codon 12. Except for RAS and RAF, anti-EGFR therapy response genetic mutations in PTEN (n=2) and PIK3CA (n=1) were found in 4.7% (3/64) of the samples. Actionable alterations were found in HER2 (n = 7), CCND2 (n = 2), NF1 (n = 1), and BRCA1 (n = 1). CONCLUSIONS: Our results illustrated that 82.5% (47/57) of the samples harbored at least one actionable genetic alteration identified by NGS. HER2 amplifications or mutations, which were identified in 12.3% of the tissues, defined a unique molecular subtype of CRC. The study suggests that high-throughput NGS testing in CRC tissues is a comprehensive and efficient genomic profiling assay to guide personalized therapy. Impact Journals LLC 2017-09-27 /pmc/articles/PMC5739621/ /pubmed/29285234 http://dx.doi.org/10.18632/oncotarget.21349 Text en Copyright: © 2017 Hou et al. http://creativecommons.org/licenses/by/3.0/ This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) (CC-BY), which permits unrestricted use and redistribution provided that the original author and source are credited.
spellingShingle Research Paper
Hou, Helei
Liu, Dong
Zhang, Chuantao
Jiang, Yanxia
Lu, Guifang
Zhou, Na
Yang, Xiaonan
Zhang, Xiaoping
Li, Zhuokun
Zhu, Hongmei
Qian, Zhaoyang
Zhang, Xiaochun
Targeted next generation sequencing in Chinese colorectal cancer patients guided anti-EGFR treatment and facilitated precision cancer medicine
title Targeted next generation sequencing in Chinese colorectal cancer patients guided anti-EGFR treatment and facilitated precision cancer medicine
title_full Targeted next generation sequencing in Chinese colorectal cancer patients guided anti-EGFR treatment and facilitated precision cancer medicine
title_fullStr Targeted next generation sequencing in Chinese colorectal cancer patients guided anti-EGFR treatment and facilitated precision cancer medicine
title_full_unstemmed Targeted next generation sequencing in Chinese colorectal cancer patients guided anti-EGFR treatment and facilitated precision cancer medicine
title_short Targeted next generation sequencing in Chinese colorectal cancer patients guided anti-EGFR treatment and facilitated precision cancer medicine
title_sort targeted next generation sequencing in chinese colorectal cancer patients guided anti-egfr treatment and facilitated precision cancer medicine
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5739621/
https://www.ncbi.nlm.nih.gov/pubmed/29285234
http://dx.doi.org/10.18632/oncotarget.21349
work_keys_str_mv AT houhelei targetednextgenerationsequencinginchinesecolorectalcancerpatientsguidedantiegfrtreatmentandfacilitatedprecisioncancermedicine
AT liudong targetednextgenerationsequencinginchinesecolorectalcancerpatientsguidedantiegfrtreatmentandfacilitatedprecisioncancermedicine
AT zhangchuantao targetednextgenerationsequencinginchinesecolorectalcancerpatientsguidedantiegfrtreatmentandfacilitatedprecisioncancermedicine
AT jiangyanxia targetednextgenerationsequencinginchinesecolorectalcancerpatientsguidedantiegfrtreatmentandfacilitatedprecisioncancermedicine
AT luguifang targetednextgenerationsequencinginchinesecolorectalcancerpatientsguidedantiegfrtreatmentandfacilitatedprecisioncancermedicine
AT zhouna targetednextgenerationsequencinginchinesecolorectalcancerpatientsguidedantiegfrtreatmentandfacilitatedprecisioncancermedicine
AT yangxiaonan targetednextgenerationsequencinginchinesecolorectalcancerpatientsguidedantiegfrtreatmentandfacilitatedprecisioncancermedicine
AT zhangxiaoping targetednextgenerationsequencinginchinesecolorectalcancerpatientsguidedantiegfrtreatmentandfacilitatedprecisioncancermedicine
AT lizhuokun targetednextgenerationsequencinginchinesecolorectalcancerpatientsguidedantiegfrtreatmentandfacilitatedprecisioncancermedicine
AT zhuhongmei targetednextgenerationsequencinginchinesecolorectalcancerpatientsguidedantiegfrtreatmentandfacilitatedprecisioncancermedicine
AT qianzhaoyang targetednextgenerationsequencinginchinesecolorectalcancerpatientsguidedantiegfrtreatmentandfacilitatedprecisioncancermedicine
AT zhangxiaochun targetednextgenerationsequencinginchinesecolorectalcancerpatientsguidedantiegfrtreatmentandfacilitatedprecisioncancermedicine